PHOTOCURE PHO Innsidehandel

Photocure ASA: Notification of primary insider transaction

31. October 2025 kl. 08:24
Original kilde

Oslo, Norway, 31 October 2025: Board member Neal Shore has acquired 13,500 shares at a price per share of NOK 55,21. Primary insider notification pursuant to the market abuse regulation article 19 is attached.

For further information, please contact:

Photocure

CFO Erik Dahl Tel: +47 450 55 000 Email: ed@photocure.com

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com/news

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading Act.

Vedlegg

PDF
Release.pdf
PDF
20251030_Photocure_ASA_Primary_insider_notification_Neal_Shore_MAR_art_19_14238706_1.pdf

Andre nyheter

18.02.2026 • Rapport

Photocure ASA: Results for the fourth quarter of 2025

Les mer →
11.02.2026

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results

Les mer →
12.01.2026

New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment

Les mer →